DSpace Collection:https://hdl.handle.net/10171/188532024-03-29T13:31:29Z2024-03-29T13:31:29ZCorrigendum: Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus (vol 10, 1151, 2019)https://hdl.handle.net/10171/679582024-01-29T12:12:12Z2020-01-01T00:00:00ZTitle: Corrigendum: Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus (vol 10, 1151, 2019)
Abstract: Reference 86 was also included as “Escacena N. Cellular
medication as a therapeutic alternative in chronic critical
limb ischemia in diabetic patients without the possibility of
revascularization. Dissertation Thesis. Sevilla Spain: University
of Sevilla. (2016)”. This reference should be included as number
107 “Escacena N. Cellular medication as a therapeutic alternative
in chronic critical limb ischemia in diabetic patients without the
possibility of revascularization (Dissertation Thesis). University of
Sevilla, Seville, Spain (2016).”2020-01-01T00:00:00ZHaematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantationhttps://hdl.handle.net/10171/663282024-01-29T12:45:58Z2020-01-01T00:00:00ZTitle: Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation
Abstract: Background The role of high-dose chemotherapy
with autologous stem cell transplantation (ASCT) in
the treatment of soft-tissue sarcoma (STS) remains an
unsettled issue. Prospective clinical trials failed to prove
a benefit of the procedure but were limited by small and
heterogeneous patient cohorts. Thus, it is unknown if ASCT
may be a valuable treatment option in specific patient
subgroups.
Methods The purpose of this study was to investigate
the value of ASCT according to histological subtype in STS
patients who were registered in the European Society for
Blood and Marrow Transplantation database between 1996
and 2016.
Results Median progression-free (PFS) and overall
survival (OS) in the entire cohort of 338 patients were 8.3
and 19.8 months, respectively, and PFS and OS at 5 years
were 13% and 25%, respectively. Analysis of outcomes
in different subgroups showed that younger age, better
remission status before transplantation and melphalanbased preparative regimen were predictive of benefit from
ASCT, whereas histology and grading had no statistically
significant impact.
Conclusions Outcomes after ASCT compared favorably
to those of recent trials on conventional chemotherapies
and targeted therapies in STS, including histology-tailored
approaches. ASCT, thus, should be reinvestigated in clinical
trials focusing on defined patient subgroups.2020-01-01T00:00:00ZCurrent approaches for the recreation of cardiac ischaemic environment in vitrohttps://hdl.handle.net/10171/659762023-06-12T05:08:54Z2023-01-01T00:00:00ZTitle: Current approaches for the recreation of cardiac ischaemic environment in vitro
Abstract: Myocardial ischaemia is one of the leading dead causes worldwide. Although animal experiments have histor-ically provided a wealth of information, animal models are time and money consuming, and they usually miss typical human patient's characteristics associated with ischemia prevalence, including aging and comorbidities. Generating reliable in vitro models that recapitulate the human cardiac microenvironment during an ischaemic event can boost the development of new drugs and therapeutic strategies, as well as our understanding of the underlying cellular and molecular events, helping the optimization of therapeutic approaches prior to animal and clinical testing. Although several culture systems have emerged for the recreation of cardiac physiology, mimicking the features of an ischaemic heart tissue in vitro is challenging and certain aspects of the disease process remain poorly addressed. Here, current in vitro cardiac culture systems used for modelling cardiac ischaemia, from self-aggregated organoids to scaffold-based constructs and heart-on-chip platforms are described. The advantages of these models to recreate ischaemic hallmarks such as oxygen gradients, patho-logical alterations of mechanical strength or fibrotic responses are highlighted. The new models represent a step forward to be considered, but unfortunately, we are far away from recapitulating all complexity of the clinical situations.2023-01-01T00:00:00ZDevelopment of an injectable alginate-collagen hydrogel for cardiac delivery of extracellular vesicleshttps://hdl.handle.net/10171/654912024-01-24T09:36:38Z2022-01-01T00:00:00ZTitle: Development of an injectable alginate-collagen hydrogel for cardiac delivery of extracellular vesicles
Abstract: Extracellular vesicles (EVs) are nanosized pArtículos with attractive therapeutic potential for cardiac repair. However, low retention and stability after systemic administration limit their clinical translation. As an alternative, the combination of EVs with biomaterial-based hydrogels (HGs) is being investigated to increase their exposure in the myocardium and achieve an optimal therapeutic effect. In this study, we developed and characterized a novel injectable in-situ forming HG based on alginate and collagen as a cardiac delivery vehicle for EVs. Different concentrations of alginate and collagen crosslinked with calcium gluconate were tested. Based on injectability studies, 1% alginate, 0.5 mg/mL collagen and 0.25% calcium gluconate HG was selected as the idoneous combination for cardiac administration using catheter-based systems. Rheological examination revealed that the HG possessed an internal gel structure, weak mechanical properties and low viscosity, facilitating an easy administration. In addition, EVs were successfully incorporated and homogeneously distributed in the HG. After administration in a rat model of myocardial infarction, the HG showed long-term retention in the heart and allowed for a sustained release of EVs for at least 7 days. Thus, the combination of HGs and EVs represents a promising therapeutic strategy for myocardial repair. Besides EVs delivery, the developed HG could represent a useful platform for cardiac delivery of multiple therapeutic agents.2022-01-01T00:00:00Z